Search

Your search keyword '"Nakamura, Yoshiaki"' showing total 1,891 results
Start Over Author "Nakamura, Yoshiaki"
1,891 results on '"Nakamura, Yoshiaki"'

104. Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy

Author

Nakamura, Yoshiaki, Yamanaka, Takeharu, Chin, Keisho, Cho, Haruhiko, Katai, Hitoshi, Terashima, Masanori, Misawa, Kazunari, Hirao, Motohiro, Yoshida, Kazuhiro, Oki, Eiji, Sasako, Mitsuru, Emi, Yasunori, Bando, Hideaki, Kawashima, Yoshiyuki, Fukunaga, Tetsu, Gotoh, Masahiro, Ishibashi, Takako, and Shitara, Kohei

Published
2019
Full Text
View/download PDF

106. Preliminary Simulation of the Scibar Cosmic Ray Telescope (SciCRT) at Sierra Negra

Author

Monterde Andrade, Fernando, primary, González, Luis Xavier, additional, Valdés Galicia, José Fransisco, additional, Newton-Bosch, Jania, additional, Morales Olivares, Oscar Gustavo, additional, Matsubara, Yutaka, additional, Itow, Yoshitaka, additional, Sako, Takashi, additional, Kawabata, Tetsuya, additional, Ortiz, Ernesto, additional, Hurtado, Alejandro, additional, Musalem, Octavio, additional, Taylor, Roberto, additional, Munakata, Kazuoki, additional, Kato, Chihiro, additional, Kihara, Wataru, additional, Ko, Yukino, additional, Shibata, Shoichi, additional, Takamaru, Hisanori, additional, Oshima, Akitoshi, additional, Koi, Tatsumi, additional, Kojima, Hiroshi, additional, Tsuchiya, Harufumi, additional, Watanabe, Kyoko, additional, Kozai, Masayoshi, additional, and Nakamura, Yoshiaki, additional

Published
2023
Full Text
View/download PDF

107. Supplementary Figure 2 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

108. Supplementary Table 5 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

109. Supplementary Figure 4 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

110. Supplementary Table 3 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

111. Supplementary Table 4 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

112. Supplementary Table 2 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

113. Supplementary Figure 3 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

114. Supplementary Table 1 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

115. Supplementary Table 6 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

116. Supplementary Table 7 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

117. Supplementary Figure 1 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

118. Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy

Author

Aoki, Yu, primary, Nakamura, Yoshiaki, additional, Denda, Tadamichi, additional, Ohta, Takashi, additional, Esaki, Taito, additional, Shiozawa, Manabu, additional, Yamaguchi, Kensei, additional, Yamazaki, Kentaro, additional, Sunakawa, Yu, additional, Kato, Takeshi, additional, Okano, Naohiro, additional, Taniguchi, Hiroya, additional, Sato, Taro, additional, Oki, Eiji, additional, Nishina, Tomohiro, additional, Komatsu, Yoshito, additional, Matsuhashi, Nobuhisa, additional, Goto, Masahiro, additional, Yasui, Hisateru, additional, Ohtsubo, Koushiro, additional, Moriwaki, Toshikazu, additional, Takahashi, Naoki, additional, Horita, Yosuke, additional, Boku, Shogen, additional, Wakabayashi, Masashi, additional, Ikeno, Takashi, additional, Mitani, Ryuta, additional, Yuasa, Mihoko, additional, and Yoshino, Takayuki, additional

Published
2023
Full Text
View/download PDF

119. Efficacy and safety of futibatinib for refractory advanced solid malignancies with FGFR alterations identified in circulating tumor DNA: TiFFANY, A GOZILA-affiliated Trial.

Author

Jogo, Tomoko, primary, Shinozaki, Eiji, additional, Masuishi, Toshiki, additional, Kato, Takeshi, additional, Nishina, Tomohiro, additional, Esaki, Taito, additional, Komatsu, Yoshito, additional, Kato, Ken, additional, Suzuki, Mitsuko, additional, Fuse, Nozomu, additional, Sato, Akihiro, additional, Ikeno, Takashi, additional, Nomura, Shogo, additional, Bando, Hideaki, additional, Odegaard, Justin Iver, additional, Fujii, Satoshi, additional, Ebi, Hiromichi, additional, Yoshino, Takayuki, additional, and Nakamura, Yoshiaki, additional

Published
2023
Full Text
View/download PDF

120. A PHASE IB STUDY OF PHOTOIMMUNOTHERAPY WITH ASP-1929 IN COMBINATON WITH NIVOLUMAB FOR PATIENTS WITH ADVANCED GASTRIC CANCER (GE-PIT STUDY, EPOC1901)

Author

Kadota, Tomohiro, primary, Kotani, Daisuke, additional, Yoda, Yusuke, additional, Fukutani, Miki, additional, Suzuki, Mitsuko, additional, Wakabayashi, Masashi, additional, Ikeno, Takashi, additional, Sunakawa, Hironori, additional, Nakamura, Yoshiaki, additional, Kawazoe, Akihito, additional, Fuse, Nozomu, additional, Sato, Akihiro, additional, Yano, Tomonori, additional, and Shitara, Kohei, additional

Published
2023
Full Text
View/download PDF

122. Recurrence monitoring using ctDNA in patients with metastasis of colorectal cancer: COSMOS- oligo study

Author

Oki, Eiji, primary, Nakanishi, Ryota, additional, Ando, Koji, additional, Nambara, Sho, additional, Takemasa, Ichiro, additional, Watanabe, Jun, additional, Matsuhashi, Nobuhisa, additional, Kato, Takeshi, additional, Kagawa, Yoshinori, additional, Kotaka, Masahito, additional, Hirata, Keiji, additional, Sugiyama, Masahiko, additional, Kusumoto, Tetsuya, additional, Miyamoto, Yuji, additional, Toyosaki, Kayo, additional, Kishimoto, Junji, additional, Kimura, Yasue, additional, Yoshizumi, Tomoharu, additional, and Nakamura, Yoshiaki, additional

Published
2023
Full Text
View/download PDF

128. Nivolumab in patients (pts) with advanced gastrointestinal (GI) cancers with high plasma tumor mutational burden (pTMB): Results from a SCRUM-Japan GOZILA phase II trial.

Author

Nakamura, Yoshiaki, Esaki, Taito, Nishina, Tomohiro, Komatsu, Yoshito, Yuki, Satoshi, Shinozaki, Eiji, Taniguchi, Hiroya, Kato, Takeshi, Kato, Ken, Nomura, Shogo, Ikeno, Takashi, Ishiguro, Yukiko, Takahashi, Koji, Higuchi, Tsukiko, Sato, Akihiro, Odegaard, Justin Iver, Kuwata, Takeshi, Matsushima, Kouji, Nakatsura, Tetsuya, and Yoshino, Takayuki

Published
2024
Full Text
View/download PDF

129. Circulating tumor DNA (ctDNA) dynamics in patients with colorectal cancer (CRC) with molecular residual disease: Updated analysis from GALAXY study in the CIRCULATE-JAPAN.

Author

Yukami, Hiroki, Nakamura, Yoshiaki, Mishima, Saori, Ando, Koji, Bando, Hideaki, Watanabe, Jun, Hirata, Keiji, Akazawa, Naoya, Ikeda, Masataka, Yokota, Mitsuru, Kato, Kentaro, Laliotis, George, Aushev, Vasily N., Jurdi, Adham A, Liu, Minetta, Kotani, Daisuke, Oki, Eiji, Takemasa, Ichiro, Kato, Takeshi, and Yoshino, Takayuki

Published
2024
Full Text
View/download PDF

130. Prognostic effects of co-occurring TP53 and KRAS aberrations in patients with advanced biliary tract cancer.

Author

Shibuki, Taro, Nakamura, Yoshiaki, Ueno, Makoto, Furukawa, Masayuki, Kawamoto, Yasuyuki, Itoh, Shinji, Umemoto, Kumiko, Sudo, Kentaro, Satoh, Taroh, Mizuno, Nobumasa, Asagi, Akinori, Okano, Naohiro, Shimizu, Satoshi, Bekaii-Saab, Tanios S., Strickler, John H, Fujisawa, Takao, Bando, Hideaki, Yoshino, Takayuki, Morizane, Chigusa, and Ikeda, Masafumi

Published
2024
Full Text
View/download PDF

131. Quantitative Analysis of the Concentration of Trifluridine in Tumor Hypoxic Regions Using a Novel Platform Combining Functional Endoscopy and Mass Spectrometry.

Author

Koganemaru, Shigehiro, Fuchigami, Hirobumi, Yamashita, Hiroki, Morizono, Chihiro, Sunakawa, Hironori, Kawazoe, Akihito, Nakamura, Yoshiaki, Kuboki, Yasutoshi, Shitara, Kohei, Yano, Tomonori, Doi, Toshihiko, and Yasunaga, Masahiro

Subjects
LIQUID chromatography-mass spectrometry, MASS spectrometry, DRUG discovery, OXYGEN saturation, QUANTITATIVE research, DRUG analysis
Abstract

Hypoxic regions in solid tumors are highly resistant to drugs and thus represents an obstacle in drug discovery. Currently, however, there are technical barriers in sampling human hypoxic tumors and examining drug delivery with high sensitivity and accuracy. Herein, we present a new platform combining functional endoscopy and highly sensitive liquid chromatography‐mass spectrometry (LC–MS) to assess drug delivery to hypoxic regions. Because oxygen saturation endoscopic imaging (OXEI), a functional endoscopy, can evaluate lesions and hypoxia in real‐time by simultaneously acquiring a pseudocolor map of oxygen saturation and conventional endoscopic images, this platform can be used to evaluate drug delivery with human samples from hypoxic regions. As the first clinical application of this platform, the relationship between hypoxic regions and the concentration of trifluridine (FTD) incorporated into DNA was evaluated in patients with advanced gastric cancer treated with FTD/tipiracil (FTD/TPI; n = 13) by obtaining and analysis of tissue samples by OXEI and LC–MS and vascular maturity index by CD31/α‐SMA staining ex vivo. The results showed that the concentration of FTD was significantly higher in the normoxic region than in the hypoxic region (P < 0.05) and there were significantly more immature vessels in hypoxic regions than in normoxic regions (P < 0.05). These results indicate that the platform was sufficiently sensitive to evaluate differences in drug anabolism in different oxygenic regions of human tumor tissue. This new platform allows quantitative drug analysis in hypoxic regions and is expected to initiate a new era of drug discovery and development. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

132. Quantitative spatial mapping of distorted state phases during the metal-insulator phase transition for nanoscale VO2 engineering.

Author

Ashida, Yuichi, Ishibe, Takafumi, Yang, Jinfeng, Naruse, Nobuyasu, and Nakamura, Yoshiaki

Subjects
PHASE transitions, METAL-insulator transitions, GEOMETRIC quantum phases, ELECTRON microscope techniques, TRANSITION metals, PHASE diagrams
Abstract

Vanadium dioxide (VO2) material, known for changing physical properties due to metal-insulator transition (MIT) near room temperature, has been reported to undergo a phase change depending on the strain. This fact can be a significant problem for nanoscale devices in VO2, where the strain field covers a large area fraction, spatially non-uniform, and the amount of strain can vary during the MIT process. Direct measurement of the strain field distribution during MIT is expected to establish a methodology for material phase identification. We have demonstrated the effectiveness of geometric phase analysis (GPA), high-resolution transmission electron microscopy techniques, and transmission electron diffraction (TED). The GPA images show that the nanoregions of interest are under tensile strain conditions of less than 0.4% as well as a compressive strain of about 0.7% (Rutile phase VO2[100] direction), indicating that the origin of the newly emerged TED spots in MIT contains a triclinic phase. This study provides a substantial understanding of the strain-temperature phase diagram and strain engineering strategies for effective phase management of nanoscale VO2. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

133. Supplementary Table from Rapid Screening Using Pathomorphologic Interpretation to Detect BRAFV600E Mutation and Microsatellite Instability in Colorectal Cancer

Author

Fujii, Satoshi, primary, Kotani, Daisuke, primary, Hattori, Masahiro, primary, Nishihara, Masato, primary, Shikanai, Toshihide, primary, Hashimoto, Junji, primary, Hama, Yuki, primary, Nishino, Takuya, primary, Suzuki, Mizuto, primary, Yoshidumi, Ayatoshi, primary, Ueno, Makoto, primary, Komatsu, Yoshito, primary, Masuishi, Toshiki, primary, Hara, Hiroki, primary, Esaki, Taito, primary, Nakamura, Yoshiaki, primary, Bando, Hideaki, primary, Yamada, Tomoyuki, primary, and Yoshino, Takayuki, primary

Published
2023
Full Text
View/download PDF

134. Supplementary Methods from A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors

Author

Chida, Keigo, primary, Kawazoe, Akihito, primary, Kawazu, Masahito, primary, Suzuki, Toshihiro, primary, Nakamura, Yoshiaki, primary, Nakatsura, Tetsuya, primary, Kuwata, Takeshi, primary, Ueno, Toshihide, primary, Kuboki, Yasutoshi, primary, Kotani, Daisuke, primary, Kojima, Takashi, primary, Taniguchi, Hiroya, primary, Mano, Hiroyuki, primary, Ikeda, Masafumi, primary, Shitara, Kohei, primary, Endo, Itaru, primary, and Yoshino, Takayuki, primary

Published
2023
Full Text
View/download PDF

135. Supplementary Table from Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy

Author

Chida, Keigo, primary, Kawazoe, Akihito, primary, Suzuki, Toshihiro, primary, Kawazu, Masahito, primary, Ueno, Toshihide, primary, Takenouchi, Kazumasa, primary, Nakamura, Yoshiaki, primary, Kuboki, Yasutoshi, primary, Kotani, Daisuke, primary, Kojima, Takashi, primary, Bando, Hideaki, primary, Mishima, Saori, primary, Kuwata, Takeshi, primary, Sakamoto, Naoya, primary, Watanabe, Jun, primary, Mano, Hiroyuki, primary, Ikeda, Masafumi, primary, Shitara, Kohei, primary, Endo, Itaru, primary, Nakatsura, Tetsuya, primary, and Yoshino, Takayuki, primary

Published
2023
Full Text
View/download PDF

136. Table S1 from The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer

Author

Kubota, Yohei, primary, Kawazoe, Akihito, primary, Sasaki, Akinori, primary, Mishima, Saori, primary, Sawada, Kentaro, primary, Nakamura, Yoshiaki, primary, Kotani, Daisuke, primary, Kuboki, Yasutoshi, primary, Taniguchi, Hiroya, primary, Kojima, Takashi, primary, Doi, Toshihiko, primary, Yoshino, Takayuki, primary, Ishii, Genichiro, primary, Kuwata, Takeshi, primary, and Shitara, Kohei, primary

Published
2023
Full Text
View/download PDF

137. Supplementary Figure from Rapid Screening Using Pathomorphologic Interpretation to Detect BRAFV600E Mutation and Microsatellite Instability in Colorectal Cancer

Author

Fujii, Satoshi, primary, Kotani, Daisuke, primary, Hattori, Masahiro, primary, Nishihara, Masato, primary, Shikanai, Toshihide, primary, Hashimoto, Junji, primary, Hama, Yuki, primary, Nishino, Takuya, primary, Suzuki, Mizuto, primary, Yoshidumi, Ayatoshi, primary, Ueno, Makoto, primary, Komatsu, Yoshito, primary, Masuishi, Toshiki, primary, Hara, Hiroki, primary, Esaki, Taito, primary, Nakamura, Yoshiaki, primary, Bando, Hideaki, primary, Yamada, Tomoyuki, primary, and Yoshino, Takayuki, primary

Published
2023
Full Text
View/download PDF

138. Supplementary Table S5 from A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors

Author

Chida, Keigo, primary, Kawazoe, Akihito, primary, Kawazu, Masahito, primary, Suzuki, Toshihiro, primary, Nakamura, Yoshiaki, primary, Nakatsura, Tetsuya, primary, Kuwata, Takeshi, primary, Ueno, Toshihide, primary, Kuboki, Yasutoshi, primary, Kotani, Daisuke, primary, Kojima, Takashi, primary, Taniguchi, Hiroya, primary, Mano, Hiroyuki, primary, Ikeda, Masafumi, primary, Shitara, Kohei, primary, Endo, Itaru, primary, and Yoshino, Takayuki, primary

Published
2023
Full Text
View/download PDF

139. Supplementary Figure Legends from A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors

Author

Chida, Keigo, primary, Kawazoe, Akihito, primary, Kawazu, Masahito, primary, Suzuki, Toshihiro, primary, Nakamura, Yoshiaki, primary, Nakatsura, Tetsuya, primary, Kuwata, Takeshi, primary, Ueno, Toshihide, primary, Kuboki, Yasutoshi, primary, Kotani, Daisuke, primary, Kojima, Takashi, primary, Taniguchi, Hiroya, primary, Mano, Hiroyuki, primary, Ikeda, Masafumi, primary, Shitara, Kohei, primary, Endo, Itaru, primary, and Yoshino, Takayuki, primary

Published
2023
Full Text
View/download PDF

140. Supplementary Figure S3 from A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors

Author

Chida, Keigo, primary, Kawazoe, Akihito, primary, Kawazu, Masahito, primary, Suzuki, Toshihiro, primary, Nakamura, Yoshiaki, primary, Nakatsura, Tetsuya, primary, Kuwata, Takeshi, primary, Ueno, Toshihide, primary, Kuboki, Yasutoshi, primary, Kotani, Daisuke, primary, Kojima, Takashi, primary, Taniguchi, Hiroya, primary, Mano, Hiroyuki, primary, Ikeda, Masafumi, primary, Shitara, Kohei, primary, Endo, Itaru, primary, and Yoshino, Takayuki, primary

Published
2023
Full Text
View/download PDF

141. Supplementary Figure from Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy

Author

Chida, Keigo, primary, Kawazoe, Akihito, primary, Suzuki, Toshihiro, primary, Kawazu, Masahito, primary, Ueno, Toshihide, primary, Takenouchi, Kazumasa, primary, Nakamura, Yoshiaki, primary, Kuboki, Yasutoshi, primary, Kotani, Daisuke, primary, Kojima, Takashi, primary, Bando, Hideaki, primary, Mishima, Saori, primary, Kuwata, Takeshi, primary, Sakamoto, Naoya, primary, Watanabe, Jun, primary, Mano, Hiroyuki, primary, Ikeda, Masafumi, primary, Shitara, Kohei, primary, Endo, Itaru, primary, Nakatsura, Tetsuya, primary, and Yoshino, Takayuki, primary

Published
2023
Full Text
View/download PDF

142. Data from Rapid Screening Using Pathomorphologic Interpretation to Detect BRAFV600E Mutation and Microsatellite Instability in Colorectal Cancer

Author

Fujii, Satoshi, primary, Kotani, Daisuke, primary, Hattori, Masahiro, primary, Nishihara, Masato, primary, Shikanai, Toshihide, primary, Hashimoto, Junji, primary, Hama, Yuki, primary, Nishino, Takuya, primary, Suzuki, Mizuto, primary, Yoshidumi, Ayatoshi, primary, Ueno, Makoto, primary, Komatsu, Yoshito, primary, Masuishi, Toshiki, primary, Hara, Hiroki, primary, Esaki, Taito, primary, Nakamura, Yoshiaki, primary, Bando, Hideaki, primary, Yamada, Tomoyuki, primary, and Yoshino, Takayuki, primary

Published
2023
Full Text
View/download PDF

143. Data from A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors

Author

Chida, Keigo, primary, Kawazoe, Akihito, primary, Kawazu, Masahito, primary, Suzuki, Toshihiro, primary, Nakamura, Yoshiaki, primary, Nakatsura, Tetsuya, primary, Kuwata, Takeshi, primary, Ueno, Toshihide, primary, Kuboki, Yasutoshi, primary, Kotani, Daisuke, primary, Kojima, Takashi, primary, Taniguchi, Hiroya, primary, Mano, Hiroyuki, primary, Ikeda, Masafumi, primary, Shitara, Kohei, primary, Endo, Itaru, primary, and Yoshino, Takayuki, primary

Published
2023
Full Text
View/download PDF

145. Trajectory for the Regulatory Approval of a Combination of Pertuzumab Plus Trastuzumab for Pre-treated HER2-positive Metastatic Colorectal Cancer Using Real-world Data

Author

Sakamoto, Yasutoshi, primary, Bando, Hideaki, additional, Nakamura, Yoshiaki, additional, Hasegawa, Hiromi, additional, Kuwaki, Takako, additional, Okamoto, Wataru, additional, Taniguchi, Hiroya, additional, Aoyagi, Yoshihiro, additional, Miki, Izumi, additional, Uchigata, Hiroshi, additional, Kuramoto, Naomi, additional, Fuse, Nozomu, additional, Yoshino, Takayuki, additional, and Ohtsu, Atsushi, additional

Published
2023
Full Text
View/download PDF

146. The comprehensive analysis of relationship between gut microbiome and treatment outcome of androgen deprivation therapy (ADT)-based treatment in patients with metastatic castration-sensitive and -resistant prostate cancer.

Author

Matsubara, Nobuaki, primary, Sakai, Shunsuke, additional, Yamashita, Riu, additional, Misumi, Toshihiro, additional, Shiota, Masaki, additional, Eto, Masatoshi, additional, Kato, Taigo, additional, Osawa, Takahiro, additional, Abe, Takashige, additional, Shinohara, Nobuo, additional, Nishimoto, Koshiro, additional, Yasumizu, Yota, additional, Tanaka, Nobuyuki, additional, Oya, Mototsugu, additional, Fujisawa, Takao, additional, Horasawa, Satoshi, additional, Nakamura, Yoshiaki, additional, Yoshino, Takayuki, additional, and Nonomura, Norio, additional

Published
2023
Full Text
View/download PDF

147. Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer

Author

Umemoto, Kumiko, primary, Sunakawa, Yu, additional, Ueno, Makoto, additional, Furukawa, Masayuki, additional, Mizuno, Nobumasa, additional, Sudo, Kentaro, additional, Kawamoto, Yasuyuki, additional, Kajiwara, Takeshi, additional, Ohtsubo, Koushiro, additional, Okano, Naohiro, additional, Matsuhashi, Nobuhisa, additional, Itoh, Shinji, additional, Matsumoto, Toshihiko, additional, Shimizu, Satoshi, additional, Otsuru, Toru, additional, Hasegawa, Hiroko, additional, Okuyama, Hiroyuki, additional, Ohama, Hideko, additional, Moriwaki, Toshikazu, additional, Ohta, Takashi, additional, Odegaard, Justin I., additional, Nakamura, Yoshiaki, additional, Bando, Hideaki, additional, Yoshino, Takayuki, additional, Ikeda, Masafumi, additional, and Morizane, Chigusa, additional

Published
2023
Full Text
View/download PDF

148. Validity and utility of blood tumor mutational burden is dependent on circulating tumor DNA shed

Author

Yoshino, Takayuki, primary, Mishima, Saori, additional, NAKAMURA, YOSHIAKI, additional, Tukachinsky, Hanna, additional, Taniguchi, Hiroya, additional, Kadowaki, Shigenori, additional, Kato, Ken, additional, Oki, Eiji, additional, Sato, Taroh, additional, Aoki, Daisuke, additional, Yamazaki, Kentaro, additional, Esaki, Taito, additional, Ueno, Makoto, additional, Nishina, Tomohiro, additional, Sunakawa, Yu, additional, Denda, Tadamichi, additional, Bando, Hideaki, additional, Kuramoto, Naomi, additional, Horasawa, Satoshi, additional, Abutani, Hikaru, additional, Lee, Jessica, additional, Madison, Russell, additional, and Oxnard, Geoffrey R., additional

Published
2023
Full Text
View/download PDF

149. MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress.

Author

Bekaii-Saab, Tanios S., primary, Van Cutsem, Eric, additional, Tabernero, Josep, additional, Siena, Salvatore, additional, Yoshino, Takayuki, additional, Nakamura, Yoshiaki, additional, Raghav, Kanwal Pratap Singh, additional, Cercek, Andrea, additional, Heinemann, Volker, additional, Adelberg, David E., additional, Ward, James Edward, additional, Yang, Shan, additional, Andre, Thierry, additional, and Strickler, John H, additional

Published
2023
Full Text
View/download PDF

150. Real-world outcome analysis of patients with advanced gastric and gastroesophageal adenocarcinoma with HER2-low expression treated with first-line therapy.

Author

Mulcahy, Mary Frances, primary, Nimeiri, Halla, additional, Rahma, Osama E., additional, Wills, Jonathan, additional, Del Rosario, Kristian, additional, Lien, Justin, additional, Pelossof, Raphael, additional, Ahmed, Talal, additional, Guinney, Justin, additional, Beaubier, Nike, additional, Pietrantonio, Filippo, additional, Nakamura, Yoshiaki, additional, Huerga, Iker, additional, and Yoshino, Takayuki, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results